CDMO

Samsung Biologics Q2 2026 Earnings: Revenue Rises to KRW 1,321 Billion Amid Global Manufacturing Expansion

By Editor's Desk
24 July 2026

Samsung Biologics Q2 2026 earnings rose year-over-year to KRW 1,321 billion in revenue and KRW 586 billion in operating profit, as the CDMO advanced its Rockville facility integration, Plant 5 ramp-up, and pending PolyPeptide Group acquisition.

Business CDMO Healthcare & Pharmaceuticals

Samsung Biologics Q1 2026 Results: Record Growth and Strategic U.S. Expansion

By BiotechReality Business Intelligence Desk
24 April 2026

Samsung Biologics reports a stellar start to 2026, recording KRW 1,257 billion in revenue and KRW 581 billion in operating profit, fueled by its new U.S. manufacturing presence and Plant 4 utilization.

Category: CDMO

Samsung Biologics Q2 2026 Earnings: Revenue Rises to KRW 1,321 Billion Amid Global Manufacturing Expansion

Samsung Biologics Q1 2026 Results: Record Growth and Strategic U.S. Expansion

Areas Covered

Discover More

Amgen Data Breach: Biotechnology Giant Discloses Theft of Patient Health Data in Cloud Cyberattack

Novo Nordisk Ziltivekimab ZEUS Trial: Phase 3 Cardiovascular Readout Misses Primary MACE Reduction Target

Roche Biocon Perjeta Lawsuit: Genentech Sues Over Biocon’s Breast-Cancer Biosimilar in New Jersey Court

Sanofi Q2 2026 Results: Dupixent Sales Growth Powers Record Second Quarter as Guidance is Upgraded

IQVIA Q2 2026 Results: Revenue Climbs 8.7% to $4.37 Billion, Company Raises Full-Year 2026 Guidance

GSK Q2 2026 Results: Core Operating Profit Rises 7% as Specialty Medicines and Vaccines Drive Growth